NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 TALAPRO-3 study of TALZENNA ® (talazoparib), an oral poly ADP-ribose polymerase (PARP) ...

Based on the efficacy and safety data, Oric will advance the 400mg therapy to Phase III trials, with more treatment-emergent ...

Erleada significantly reduces the risk of death by 51% in mCSPC patients compared to Nubeqa, without chemotherapy, over 24 months. The study used inverse probability of treatment weighting to ensure ...

Oric Pharmaceuticals has picked the phase 3 dose for its prostate cancer prospect, barreling into the pivotal program while ...

For prostate cancer patients with low-volume tumors and metastasis, the median overall survival was 37.13 months. Prostate cancer patients with metastatic disease and low-volume primary tumors appear ...

Patients with metastatic hormone-sensitive prostate cancer had similar overall survival no matter whether metformin was added to standard of care in a randomized trial. Metformin use was associated ...

ORIC Pharmaceuticals (ORIC) lost ~22% in extended trading after the company reported data from a Phase 1b trial for its ...

Excess body weight, as measured by BMI, is associated with improved overall survival (OS) in men with advanced prostate cancer, particularly those with metastatic castration-resistant disease, a ...